赖氨酰氧化酶（LOX）家族蛋白质与肺癌发生发展的研究进展

楚雄师范学院学报 ›› 2023, Vol. 38 ›› Issue (3): 70-75.

赖氨酰氧化酶（LOX）家族蛋白质与肺癌发生发展的研究进展

王播勇^1,2, 罗中贵^1,2, 周崇熙^1,2, 李彬^1,2, 刘如爱^1,2, 杨玺^1,2, 熊伟^1,2,*

1.大理大学基础医学院,云南大理 671000;
2.云南省高校临床生物化学检验重点实验室,云南大理 671000

收稿日期:2022-10-05 出版日期:2023-05-20 发布日期:2023-08-07
通讯作者: * 熊伟（1982–）,男,博士,教授,博士生导师,研究方向为分子生物学与肿瘤机制。E-mail：xiongwei@dali.edu.cn,Tel：18313024698
作者简介:王播勇（1995–）,男,硕士研究生,研究方向为肿瘤机制。E-mail：1622070978@qq.com, Tel： 15770672729
基金资助:
国家自然科学基金项目（No. 31760331, No. 32160167, No. 82160516）,云南省李云庆专家工作站（No. 202005AF150014）,云南省高校病理学与病理生理学硕士研究生导师团队项目（No. 2019）,云南省教育厅科研基金研究生项目（No. 2021Y808）,国家级大学生创新创业训练计划项目（No. 202110679010, 202110679042）

Advances in the Study of Lysyl Oxidase (LOX) Family Protein and Occurrence and Development of Lung Cancer

WANG Boyong^1,2, LUO Zhonggui^1,2, ZHOU Chongxi^1,2, LI Bin^1,2, LIU Ruai^1,2, YANG Xi^1,2, XIONG Wei^1,2,*

1. Basic Medical College, Dali University, Dali, Yunnan Province 671000;
2. Yunnan Provincial Key Laboratory of Clinical Biochemistry, Dali, Yunnan Province 671000

Received:2022-10-05 Online:2023-05-20 Published:2023-08-07

摘要/Abstract

摘要： 赖氨酰氧化酶（lysyl oxidase, LOX）家族由LOX和4种LOX样蛋白（lysyl oxidase like 1-4, LOXL1-4）组成,主要作用于细胞外基质（extracellular matrix, ECM）的重塑以及胶原和弹性纤维的交联。肺癌是全世界范围内第二大常见癌症,其发病率仅次于乳腺癌,死亡率第一。近年来,越来越多的研究表明,LOX家族与肺癌细胞增殖、迁移、侵袭和转移等过程密切相关。本综述介绍LOX家族各个成员在肺癌发生和进展中的作用机制及其研究进展。

关键词: 赖氨酰氧化酶（LOX）家族, 细胞外基质（ECM）, 肺癌, 发生和发展

Abstract: The lysyl oxidase (LOX) family consists of LOX and four LOX-like proteins (LOXL1, LOXL2, LOXL3, and LOXL4) that act mainly in the remodeling of the extra cellular matrix (ECM) and the cross-linking of collagen and elastic fibers. As the second most common cancer worldwide, lung cancer ranks second in incidence (second only to breast cancer) and first in mortality rate. Recently, an increasing number of studies have shown that the LOX family is closely associated with the regulation of cancer cell proliferation, migration, invasion and metastasis. This review mainly presents the mechanism and research progress of each member of the LOX family in the occurrence and progression of lung cancer.

Key words: lysyl oxidase family, extracellular matrix (ECM), lung cancer, occurrence and development

中图分类号:

R734.2

王播勇, 罗中贵, 周崇熙, 李彬, 刘如爱, 杨玺, 熊伟. 赖氨酰氧化酶（LOX）家族蛋白质与肺癌发生发展的研究进展[J]. 楚雄师范学院学报, 2023, 38(3): 70-75.

WANG Boyong, LUO Zhonggui, ZHOU Chongxi, LI Bin, LIU Ruai, YANG Xi, XIONG Wei. Advances in the Study of Lysyl Oxidase (LOX) Family Protein and Occurrence and Development of Lung Cancer[J]. Journal of Chuxiong Normal University, 2023, 38(3): 70-75.

参考文献

[1] Wang T H, Hsia S M, Shieh T M.Lysyl oxidase and the tumor microenvironment[J]. International Journal of Molecular Sciences, 2016, 18(1):62.
[2] Almacellas-Rabaiget O, Monaco P, Huertas-Martinez J, et al. LOXL2 promotes oncogenic progression in alveolar rhabdomyosarcoma independently of its catalytic activity[J]. Cancer Letters, 2020, 474(474):1-14.
[3] Xiao Q, Ge G.Lysyl oxidase, extracellular matrix remodeling and cancer metastasis[J]. Cancer Microenvironment, 2012, 5(3):261-273.
[4] Cox T R, Erler J T.Lysyl oxidase in colorectal cancer[J]. American Journal of Physiology-Gastrointestinal and Liver Physiology, 2013, 305(10):G659-G666.
[5] 梁金娥,王安琪,史煜,等.LOX家族在肿瘤中的研究进展[J].现代肿瘤医学,2019,27(20):3733-3736.
LIANG J E, WANG A Q, SHI Y, et al. Research progress of LOX family in tumors[J]. Journal of Modern Oncology, 2019, 27(20):3733-3736.
[6] 管雅喆,任萌,郭冬利,等. 肺癌筛查研究进展[J].中国肺癌杂志,2020,23(11):954-960.
GUAN Y Z, REN M, GUO D l, et al. Research progress of lung cancer screening[J]. Chinese Journal of Lung Cancer, 2020, 23(11):954-960.
[7] Xing P Y, Zhu Y X, Wang L, et al. What are the clinical symptoms and physical signs for non-small cell lung cancer before diagnosis is made? A nation-wide multicenter 10-year retrospective study in China[J]. Cancer Medicine, 2019, 8(8):4055-4069.
[8] Nilsson M, Adamo H, Bergh A, et al. Inhibition of lysyl oxidase and lysyl oxidase-like enzymes has tumour-promoting and tumour-Suppressing roles in experimental prostate cancer[J]. Scientific Reports, 2016, 6(6):19608.
[9] Rachman-Tzemah C, Zaffryar-Eilot S, Grossman M, et al. Blocking surgically induced lysyl oxidase activity reduces the risk of lung metastases[J]. Cell Reports, 2017,19(4):774-784.
[10] Gong C, Gu R, Jin H, et al. Lysyl oxidase mediates hypoxia-induced radioresistance in non-small cell lung cancer A549 cells[J]. Experimental Biology and Medicine (Maywood),2016,241(4):387-395.
[11] 展平,谢海燕. 赖氨酰氧化酶样蛋白2在肺腺癌患者中的预后价值[J]. 肿瘤学杂志,2017,23(11):973-977.
ZHAN P, XIE H Y.Prognostic value of lysyl oxidase-like protein 2 in patients with lung adenocarcinoma[J]. Journal of Oncology, 2017, 23(11):973-977.
[12] Wilgus M L, Borczuk A C, Stoopler M, et al. Lysyl oxidase: a lung adenocarcinoma biomarker of invasion and survival[J]. Cancer, 2011, 117(10):2186-2191.
[13] Liu J, Ping W, Zu Y, et al. Correlations of lysyl oxidase with MMP2/MMP9 expression and its prognostic value in non-small cell lung cancer[J].International Journal of Clinical and Experimental Pathology, 2014, 7(9):6040-6047.
[14] Hou X, Du H, Quan X, et al. Silibinin inhibits NSCLC metastasis by targeting the EGFR/LOX pathway[J]. Frontiers in Immunology, 2018,9(9):21.
[15] Lindskog C, Edlund K, Mattsson J S, et al. Immunohistochemistry-based prognostic biomarkers in NSCLC: novel findings on the road to clinical use?[J]. Expert Review of Molecular Diagnostics, 2015, 15(4):471-490.
[16] Lee G H, Kim D S, Chung M J, et al. Lysyl oxidase-like-1 enhances lung metastasis when lactate accumulation and monocarboxylate transporter expression are involved[J]. Oncology Letters, 2011, 2(5):831-838.
[17] Le Calve B, Griveau A, Vindrieux D, et al. Lysyl oxidase family activity promotes resistance of pancreatic ductal adenocarcinoma to chemotherapy by limiting the intratumoral anticancer drug distribution[J]. Oncotarget, 2016, 7(22):32100-32112.
[18] Barker H E, Cox T R, Erler J T.The rationale for targeting the LOX family in cancer[J]. Nature Reviews Cancer, 2012,12(8):540-552.
[19] Alsofi L, Daley E, Hornstra I, et al. Sex-linked skeletal phenotype of lysyl oxidase like-1 mutant mice[J]. Calcified Tissue International, 2016, 98(2):172-185.
[20] Zeltz C, Pasko E, Cox T R, et al. LOXL1 is regulated by integrin alpha11 and promotes non-small cell lung cancer tumorigenicity[J]. Cancers (Basel), 2019, 11(5):705.
[21] Hollosi P, Yakushiji J K, Fong K S, et al. Lysyl oxidase-like 2 promotes migration in noninvasive breast cancer cells but not in normal breast epithelial cells[J]. International Journal of Cancer, 2009, 125(2):318-327.
[22] Herranz N, Dave N, Millanes-Romero A, et al. Lysyl oxidase-like 2 (LOXL2) oxidizes trimethylated lysine 4 in histone H3[J]. FEBS Journal, 2016, 283(23):4263-4273.
[23] Ye M, Zhang J, Guo T, et al. MiR-504 inhibits cell proliferation and invasion by targeting LOXL2 in non-small cell lung cancer[J]. Biomedicine and Pharmacotherapy, 2018, 97(97):1289-1295.
[24] Zhan P, Lv X J, Ji Y N, et al. Increased lysyl oxidase-like 2 associates with a poor prognosis in non-small cell lung cancer[J]. European Clinical Respiratory Journal, 2018, 12(2):712-720.
[25] Mizuno K, Seki N, Mataki H, et al. Tumor-suppressive microRNA-29 family inhibits cancer cell migration and invasion directly targeting LOXL2 in lung squamous cell carcinoma[J]. International Journal of Oncology, 2016,48(2):450-460.
[26] Kamikawaji K, Seki N, Watanabe M, et al. Regulation of LOXL2 and SERPINH1 by antitumor microRNA-29a in lung cancer with idiopathic pulmonary fibrosis[J]. Journal of Human Genetics, 2016, 61(12):985-993.
[27] Peng D H, Ungewiss C, Tong P, et al. ZEB1 induces LOXL2-mediated collagen stabilization and deposition in the extracellular matrix to drive lung cancer invasion and metastasis[J]. Oncogene, 2017, 36(14):1925-1938.
[28] Kasashima H, Yashiro M, Okuno T, et al. Significance of the lysyl oxidase members lysyl Oxidase like 1, 3, and 4 in gastric cancer[J]. Digestion, 2018, 98(4):238-248.
[29] Sebban S, Golan-Gerstl R, Karni R, et al. Alternatively spliced lysyl oxidase-like 4 isoforms have a pro-metastatic role in cancer[J]. Clinical and Experimental Metastasis, 2013, 30(1):103-117.
[30] Ye M, Song Y, Pan S, et al. Evolving roles of lysyl oxidase family in tumorigenesis and cancer therapy[J].Pharmacology and Therapeutics, 2020, 215:107633.
[31] 张晓春. 2019肺癌精准治疗的前沿与展望[J]. 医学研究生学报,2019,32(10):1009-1013.
ZHANG X C.Frontier and prospect of precise treatment of lung cancer in 2019[J]. Journal of Medical Postgraduates, 2019, 32(10):1009-1013.
[32] Zhang Y, Jiang W L, Yang J Y, et al. Downregulation of lysyl oxidase-like 4 LOXL4 by miR-135a-5p promotes lung cancer progression in vitro and in vivo[J]. Journal of Cellular Physiology, 2019, 234(10):18679-18687.
[33] Xie S, Liu G, Huang J, et al. miR-210 promotes lung adenocarcinoma proliferation, migration, and invasion by targeting lysyl oxidase-like 4[J]. Journal of Cellular Physiology, 2019, 234(8):14050-14057.